Sumatriptan Succinate Tablet, Film Coated
Product Images NDC 50090-5939
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sumatriptan Succinate (NDC 50090-5939). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Label Image (Lbl500905939)
Sumatriptan-figure-1 (Sumatriptan Figure 1)
This is a figure showing the estimated probability of achieving initial headache relief within 4 hours of treatment with oral sumatriptan. The data displayed is pooled from 3 clinical trials that have provided evidence of efficacy for the drug. The figure shows the probability of obtaining headache relief over time, with different dosages of the drug (25 mg, 50 mg, and 100 mg) and a placebo. The averages displayed are based on a Kaplan-Meier plot with patients not achieving response and/or taking rescue within 240 minutes censored to 240 minutes.*
Sumatriptan-figure-2 (Sumatriptan Figure 2)
The text describes a figure (Figure 2) which illustrates the estimated probability of patients taking a second dose of Sumatriptan Succinate tablets, or other medication for treating migraine, within 24 hours of the initial dose. The figure uses data from Pooled Trials 1, 2, and 3, and shows the probability percentage against time in hours from initial dose on a Kaplan-Meier plot. The plot also takes into account patients who had no response to the initial dose and does not allow for remedication within 2 hours postdose.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.